Studies have shown that the anti-tumor effect of CTLA-4 blockade therapy depends on specific Bacteroides species, especially Bacteroides thetaiotaomicron and B. fragilis, which can enhance tumor immune responses by promoting T cell activation and tumor-infiltrating lymphocyte function [231]. Here, CTLA4 is linked to neoplasm.